



Technical Data Sheet

Recombinant Human Pigment Epithelium-derived Factor (Human PEDF)

Human PEDF

PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers.

Catalog Number:	RC213-19
Source:	<i>Escherichia coli</i> .
Molecular Weight:	Approximately 44.5 KDa, a single non-glycosylated polypeptide chain containing 400 amino acids.
Quantity:	5ug/20ug/1000µg
Purity:	>95% by SDS-PAGE and HPLC analyses.
Biological Activity:	Data Not Available.
Physical Appearance:	Sterile Filtered White Lyophilized (freeze-dried) powder.
Formulation:	Lyophilized from a 0.2µm filtered concentrated (1.0mg/ml) solution in 20mM PB, pH7.4, 150mM NaCl.
AA Sequence:	MQNPASPPEEGSPDPDSTGALVEEEDPFFKVPVNKLA AAVSNFGYDLYRVRSSMSPTTNVLLS PLSVATALSALSGLAEQRTESIHRALYYDLISSPDIHGTYKELLDTVTAPQKNLKSASRIVFEKRLRI KSSFVAPLEKSYGTRPRVLTGNPRLDLQEIINWVQAQMKGKLARSTKEIPDEISILLGV AHFKG QWVTKFDSRKTSLDFYLDEERTVRVPMMSDPKAVLRYGLDSDLCKIAQLPLTGSM SIIFFLPL KVTONLTLIEESLTSEFIHDIDRELKTVQAVLTPKCLKLSYEGEVTKSLOEMKQLSLFDSPDFSKIT GKPIKLTQVEHRAGFEWNEDGAGTTPSPGLQPAHLTFPLDYHLNQPFIFVLRD TDTGALLFIGKI LDPRGP



Endotoxin:	Less than 1EU/ μ g of rHuPEDF as determined by LAL method.
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at $\leq -20^{\circ}\text{C}$. Further dilutions should be made in appropriate buffered solutions.
Storage:	This lyophilized preparation is stable at $2-8^{\circ}\text{C}$, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at $2-8^{\circ}\text{C}$. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C . Avoid repeated freeze/thaw cycles.
Usage:	This material is offered by Bio Basic Inc for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.